Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
LaggingEyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E technology (Durasert E) for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU1, is an investigational sustained delivery treatment for vascular endothelial growth factor (VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI) with the Company's bioerodible Durasert E drug delivery technology.
In the company’s own words · 10-K filed Mar 5, 2026 · SEC EDGAR
Business segments
Q1 2026 · $229.0KThe company’s own SEC segment disclosure.
- Royalty$141.0K62%
- License And Collaboration Agreement$88.0K38%
EyePoint, Inc. (EYPT) reported revenue of $696K in Q1 2026 (quarter ended Mar 31, 2026), down 97% from the same quarter a year earlier. That came with net loss of $85M. For the full year FY2025, revenue was $31M (−28% year on year) and net income −$232M. Its largest product in Q1 2026 was Royalty at $141K, 62% of the disclosed total, well ahead of License And Collaboration Agreement at 38%.
Raw charts
10 series · TTMAs reported to the SEC, without any scoring.